Skip to main content
. 2021 Mar 4;11(10):4790–4808. doi: 10.7150/thno.57456

Figure 3.

Figure 3

LV mass increases progressively after DUSP5 siRNA+T3 therapy in young adult (5-week-old) mice. (A) Diagram showing the time points before (a) and after DUSP5 siRNA+T3 therapy (b to e) at which LV mass was determined using echocardiography. (B-E) Serial determinations of LV mass before and after therapy with scrambled siRNA (control) (B), DUSP5 scrambled siRNA+T3 (C), DUSP5 siRNA (D) and DUSP5 siRNA+T3 (E) (n = 10 mice per group). Comparisons were made using a paired 2-tailed t-test between time points A and E. ***P < 0.001. (F) Relative change (%) in LV mass between the start of therapy and 4-week after therapy (n = 10 pairs per group). Comparisons were made using ANOVA with Sidak multiple comparison test; only within group P-values are shown. Individual data points and mean ± s.e.m are shown. ***P < 0.001.